Biotech · Private company · Durham, NC, US
Atsena Therapeutics Inc.
Track this companyFree. Adds Atsena Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials22 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- ATSN-201Phase 3 · X-linked RetinoschisisClinicalTrials.gov · fetched Nov 12, 2026
- 1% PrednisolonePhase 2 · Leber Congenital AmaurosisClinicalTrials.gov · fetched Nov 12, 2026
- ATSN-101Phase 2 · Leber Congenital AmaurosisClinicalTrials.gov · fetched Nov 12, 2026
- ATSN-101 Diluent SolutionPhase 2 · Leber Congenital AmaurosisClinicalTrials.gov · fetched Nov 12, 2026
- PrednisonePhase 2 · Leber Congenital AmaurosisClinicalTrials.gov · fetched Nov 12, 2026
- Triamcinalone AcetonidePhase 2 · Leber Congenital AmaurosisClinicalTrials.gov · fetched Nov 12, 2026
- Trimethoprim/polymyxin BPhase 2 · Leber Congenital AmaurosisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- ATSN-201 Gene Therapy in RS1-Associated X-linked RetinoschisisPHASE3 · RECRUITING · started Aug 22, 2023ClinicalTrials.gov NCT05878860 · fetched Nov 12, 2026
- Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2DPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 22, 2019ClinicalTrials.gov NCT03920007 · fetched Nov 12, 2026
NIH awards2
- Manufacturing Development and Commercial Readiness of an Adeno-Associated Virus-Based Gene Therapy for the Treatment of Leber Congenital Amaurosis Type 1Fiscal year 2026 · $731KNIH RePORTER 5R44EY037156-02 · fetched Nov 12, 2026
- Manufacturing Development and Commercial Readiness of an Adeno-Associated Virus-Based Gene Therapy for the Treatment of Leber Congenital Amaurosis Type 1Fiscal year 2025 · $870.7KNIH RePORTER 1R44EY037156-01 · fetched Nov 12, 2026